Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Research & Development (2016 - 2025)

Historic Research & Development for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $68.8 million.

  • Corcept Therapeutics' Research & Development rose 1602.74% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.4 million, marking a year-over-year increase of 1256.37%. This contributed to the annual value of $246.9 million for FY2024, which is 3392.08% up from last year.
  • Per Corcept Therapeutics' latest filing, its Research & Development stood at $68.8 million for Q3 2025, which was up 1602.74% from $60.5 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Research & Development peaked at $70.3 million during Q4 2024, and registered a low of $28.1 million during Q3 2021.
  • For the 5-year period, Corcept Therapeutics' Research & Development averaged around $45.6 million, with its median value being $43.3 million (2023).
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 1705.98% in 2021, then soared by 4884.64% in 2023.
  • Corcept Therapeutics' Research & Development (Quarter) stood at $28.5 million in 2021, then grew by 28.88% to $36.8 million in 2022, then soared by 48.85% to $54.7 million in 2023, then increased by 28.5% to $70.3 million in 2024, then dropped by 2.07% to $68.8 million in 2025.
  • Its last three reported values are $68.8 million in Q3 2025, $60.5 million for Q2 2025, and $60.7 million during Q1 2025.